Affinity Asset Advisors’s Cogent Biosciences COGT Stock Holding History

Affinity Asset Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.4M	Sell	450,000 -300,000	-40%	-$10.5M	0.79%	38
2026 Q1	$28.9M	Buy	750,000 +400,000	+114%	+$14.8M	1.49%	21
2025 Q4	$12.4M	Buy	+350,000	New	+$9.84M	0.71%	40
2023 Q2	–	Sell	-143,064	Closed	-$1.54M	–	75
2023 Q1	$1.54M	Sell	143,064 -50,000	-26%	-$640K	0.51%	48
2022 Q4	$2.23M	Buy	193,064 +38,977	+25%	+$483K	0.88%	36
2022 Q3	$2.3M	Buy	154,087 +29,087	+23%	+$399K	0.64%	35
2022 Q2	$1.13M	Buy	+125,000	New	+$853K	0.48%	39

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Affinity Asset Advisors's COGT Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Cogent Biosciences (COGT) stake by 40% in Q2 2026, selling an estimated $10.5M and leaving 450,000 shares worth $17.4M. The position accounts for 0.79% of the portfolio, ranked #38.

Affinity Asset Advisors first reported a position in COGT in Q2 2022 and has held it in 7 quarters since. The position peaked at $28.9M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Affinity Asset Advisors held 450,000 shares of Cogent Biosciences worth $17.4M as of Q2 2026.
Affinity Asset Advisors sold 300,000 Cogent Biosciences shares in Q2 2026, an estimated $10.5M.
Cogent Biosciences made up 0.79% of Affinity Asset Advisors's portfolio in Q2 2026, its #38 holding.
Affinity Asset Advisors first reported a position in Cogent Biosciences in Q2 2022 and has held it in 7 quarters since.
Affinity Asset Advisors's Cogent Biosciences position peaked at $28.9M in Q1 2026.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.